


February 2026 Dashboard

Letters of Intent (LOIs)

Since the pCPA's inception, 768 negotiations have reached a letter of intent (LOI), including:

- 270 oncology drugs
- 92 biosimilars
- 93 drugs for rare diseases (DRD)




Savings

pCPA activities saved jurisdictions an estimated **\$4.87B** in 2024-25:




- **\$3.94B** from brand-name drugs
- **\$935M** from generic drugs

Since 2010, cumulative savings are estimated to be **\$28.8B**





HTA and pCPA volumes

- The pCPA engaged and concluded a record number of negotiations in 2025, in response to sustained high volume of health technology assessment (HTA) reimbursement recommendations in recent years.
- Numbers of HTA reimbursement recommendations are expected to be similar in 2026 as those in 2025, and pCPA negotiation volumes are also projected to be similar.



pCPA activity


- The number of files under consideration has moderately increased from summer 2025.
- The pCPA is committed to further decreasing the time under consideration.
- The number of active negotiations remained strong after hitting a record high in the summer of 2025.



"Files under consideration" represents files between the HTA recommendation and pCPA engagement. "Active negotiations" are files that have been engaged but have not concluded.

pCPA timelines


- Between 2020 and 2025, the typical time under consideration improved from 99 business days to 32 business days, a 67% decrease.*
- Between 2020 and 2025, the total timeline improved from 219 business days to 81 business days, a 63% decrease.*



*Not all negotiations initiated in 2025 have concluded. The pCPA expects that as outstanding negotiations conclude, median timelines for 2025 will increase to be similar to 2024 timelines.

Oncology drugs

- Timelines have improved for both time under consideration and active negotiation since 2020 for oncology drugs. The median time for under consideration has decreased from 45 business days, in 2020 to 30 business days in 2025. For time spent actively negotiating, timelines have decreased from a median of 103 business days to 40 business days.*



*Not all negotiations initiated in 2025 have concluded. The pCPA expects that as outstanding negotiations conclude, median timelines for 2025 will increase to be similar to 2024 timelines.